{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:06:19Z","timestamp":1790287579941,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,15]]},"DOI":"10.7759\/cureus.25960","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T13:40:56Z","timestamp":1655300456000},"source":"Crossref","is-referenced-by-count":2,"title":["Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis"],"prefix":"10.7759","author":[{"given":"Maleesha","family":"Jayasinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Jena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malay","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Karnakoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minollie Suzanne","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mueez Alam","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.332123","article-title":"Motor neuron replacement therapy for amyotrophic lateral sclerosis","volume":"17","author":"Liu B","year":"2022","unstructured":"Liu B, Li M, Zhang L, Chen Z, Lu P. Motor neuron replacement therapy for amyotrophic lateral sclerosis. Neural Regen Res. 2022, 17:1633-9. 10.4103\/1673-5374.332123","journal-title":"Neural Regen Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton AE","year":"2014","unstructured":"Renton AE, Chi\u00f2 A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014, 17:17-23. 10.1038\/nn.3584","journal-title":"Nat Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.335154","article-title":"Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet","volume":"17","author":"Lerskiatiphanich T","year":"2022","unstructured":"Lerskiatiphanich T, Marallag J, Lee JD. Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet. Neural Regen Res. 2022, 17:1975-7. 10.4103\/1673-5374.335154","journal-title":"Neural Regen Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.314289","article-title":"Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis","volume":"17","author":"Zakharova MN","year":"2022","unstructured":"Zakharova MN, Abramova AA. Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis. Neural Regen Res. 2022, 17:65-73. 10.4103\/1673-5374.314289","journal-title":"Neural Regen Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-01919-9","article-title":"Qualitative measures that assess functional disability and quality of life in ALS","volume":"20","author":"Hartmaier SL","year":"2022","unstructured":"Hartmaier SL, Rhodes T, Cook SF, et al.. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022, 20:12. 10.1186\/s12955-022-01919-9","journal-title":"Health Qual Life Outcomes"},{"key":"ref6","article-title":"Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Cruz MP","year":"2018","unstructured":"Cruz MP. Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P T. 2018, 43:25-8.","journal-title":"P T"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.17-62","article-title":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?","volume":"62","author":"Watanabe K","year":"2018","unstructured":"Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?. J Clin Biochem Nutr. 2018, 62:20-38. 10.3164\/jcbn.17-62","journal-title":"J Clin Biochem Nutr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27467","article-title":"Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19","volume":"65","author":"Brooks BR","year":"2022","unstructured":"Brooks BR, Pioro EP, Katz J, Takahashi F, Takei K, Zhang J, Apple S. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19. Muscle Nerve. 2022, 65:180-6. 10.1002\/mus.27467","journal-title":"Muscle Nerve"},{"key":"ref9","unstructured":"Phase 3 study of MCI-186 for treatment of amyotrophic lateral sclerosis. (2018). https.\/\/clinicaltrials.gov\/ct2\/show\/NCT01492686."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-3254","article-title":"Familial amyotrophic lateral sclerosis induced by gene mutation of SOD1G142A: a case report","volume":"10","author":"Cui X","year":"2021","unstructured":"Cui X, Gao M, Huang Y, Liu X, Xu Y. Familial amyotrophic lateral sclerosis induced by gene mutation of SOD1G142A: a case report. Ann Palliat Med. 2021, 10:12900-5. 10.21037\/apm-21-3254","journal-title":"Ann Palliat Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel S","year":"2022","unstructured":"Witzel S, Maier A, Steinbach R, et al.. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022, 79:121-30. 10.1001\/jamaneurol.2021.4893","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2017.1364269","article-title":"Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","year":"2017","unstructured":"Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017, 18.55-63. 10.1080\/21678421.2017.1364269","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080705","article-title":"Improved long-term survival with edaravone therapy in patients with amyotrophic lateral sclerosis: a retrospective single-center study in Japan","volume":"14","author":"Houzen H","year":"2021","unstructured":"Houzen H, Kano T, Horiuchi K, Wakita M, Nagai A, Yabe I. Improved long-term survival with edaravone therapy in patients with amyotrophic lateral sclerosis: a retrospective single-center study in Japan. Pharmaceuticals (Basel). 2021, 14:705. 10.3390\/ph14080705","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref14","article-title":"Efficacy and safety of edaravone in amyotrophic lateral sclerosis patients in Indian population","volume":"70","author":"Tomar S","year":"2022","unstructured":"Tomar S, Gupta S, Singal A, Soni R. Efficacy and safety of edaravone in amyotrophic lateral sclerosis patients in Indian population. J Assoc Physicians India. 2022, 70:11-2.","journal-title":"J Assoc Physicians India"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis","volume":"267","author":"Lunetta C","year":"2020","unstructured":"Lunetta C, Moglia C, Lizio A, et al.. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020, 267:3258-67. 10.1007\/s00415-020-09993-z","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-04055-3","article-title":"Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients","volume":"41","author":"Park JM","year":"2020","unstructured":"Park JM, Kim SY, Park D, Park JS. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. 2020, 41:119-23. 10.1007\/s10072-019-04055-3","journal-title":"Neurol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10818","article-title":"Post-marketing experience of edaravone in amyotrophic lateral sclerosis: a clinical perspective and comparison with the clinical trials of the drug","volume":"12","author":"Ortiz JF","year":"2020","unstructured":"Ortiz JF, Khan SA, Salem A, Lin Z, Iqbal Z, Jahan N. Post-marketing experience of edaravone in amyotrophic lateral sclerosis: a clinical perspective and comparison with the clinical trials of the drug. Cureus. 2020, 12:e10818. 10.7759\/cureus.10818","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-020-01430-2","article-title":"Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience","volume":"121","author":"Ismail II","year":"2021","unstructured":"Ismail II, Massoud F, Kamel WA, Al-Hashel JY. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience. Acta Neurol Belg. 2021, 121:1591-7. 10.1007\/s13760-020-01430-2","journal-title":"Acta Neurol Belg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.18502\/cjn.v20i1.6373","article-title":"Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: a parallel-group single-blind trial","volume":"20","author":"Eishi-Oskouei A","year":"2021","unstructured":"Eishi-Oskouei A, Basiri K. Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: a parallel-group single-blind trial. Curr J Neurol. 2021, 20:1-7. 10.18502\/cjn.v20i1.6373","journal-title":"Curr J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-020-01382-7","article-title":"Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina","volume":"121","author":"Quarracino C","year":"2021","unstructured":"Quarracino C, Bendersky M, Rey R, Rodr\u00edguez GE. Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina. Acta Neurol Belg. 2021, 121:1519-23. 10.1007\/s13760-020-01382-7","journal-title":"Acta Neurol Belg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2019.1572191","article-title":"Early post-marketing experience with edaravone in an unselected group of patients with ALS","volume":"20","author":"Abraham A","year":"2019","unstructured":"Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2019, 20:260-3. 10.1080\/21678421.2019.1572191","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/101624-ethnical-disparities-in-response-to-edaravone-in-patients-with-amyotrophic-lateral-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:03Z","timestamp":1707507963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/101624-ethnical-disparities-in-response-to-edaravone-in-patients-with-amyotrophic-lateral-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.25960","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}